Management of metastatic castration-resistant prostate cancer: recent advances.
about
Peptidomimetic targeting of critical androgen receptor-coregulator interactions in prostate cancerTargeting HOX transcription factors in prostate cancerSafety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer.IGF2 revs the steroidogenesis engine.Loss of Androgen-Regulated MicroRNA 1 Activates SRC and Promotes Prostate Cancer Bone Metastasis.AR-regulated TWEAK-FN14 pathway promotes prostate cancer bone metastasismiR-539 inhibits prostate cancer progression by directly targeting SPAG5Adaptation or selection--mechanisms of castration-resistant prostate cancer.Enzalutamide: a review of its use in metastatic, castration-resistant prostate cancer.Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics.An arranged marriage for precision medicine: hypoxia and genomic assays in localized prostate cancer radiotherapy.Radium-223 dichloride: a review of its use in patients with castration-resistant prostate cancer with symptomatic bone metastases.GATA2 as a potential metastasis-driving gene in prostate cancer.Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer.Secretory clusterin contributes to oxaliplatin resistance by activating Akt pathway in hepatocellular carcinoma.Prostate cancer metastasis-driving genes: hurdles and potential approaches in their identification.GP73 level determines chemotherapeutic resistance in human hepatocellular carcinoma cells.Secretory Clusterin Mediates Oxaliplatin Resistance via the Gadd45a/PI3K/Akt Signaling Pathway in Hepatocellular Carcinoma.
P2860
Q28291526-FBD27377-42F8-4930-BFFD-4515998CDA4FQ31150248-881EC446-90F6-48D7-A866-6672945EABDBQ33440646-F0C8C249-FC14-4868-ADE2-658BE253BB1DQ33881128-6D6A8B39-EEEF-47EF-8C85-96A165BEC428Q35573029-A7B52303-F3A1-485A-B0A5-EF4690F6C4BFQ35600629-BEFEEB1F-C3E8-4330-A568-59A3E2B9ED1AQ36758507-835B662E-6590-4036-83DD-41BF24D59C83Q38068116-DAB343FB-72C6-4137-A69D-A3B87F62E6C2Q38152744-8AE40C92-7A9C-4D60-A801-3BB02D4BB374Q38181005-380F8585-C407-48AB-98C7-AEF6753BC621Q38192714-CA082FE8-3ACA-41F3-B297-D4F9332CA651Q38194528-4FA49E1D-C66C-4E19-A36C-E7F87A922011Q38457785-67EFB6F5-93B3-4869-A154-386C69BFC967Q38919065-2105031E-FF7D-48FF-946B-69B3741A7761Q39218247-21842A6B-B02A-4718-B902-412B5E9F96F3Q41902787-F2206A23-58D2-4D84-B307-4B00821FC581Q49189683-1C2A84A1-9E6D-4D44-8080-B636C235FFF8Q55080589-5DC384A5-2CA0-476C-9F17-13B8C90DEEA8
P2860
Management of metastatic castration-resistant prostate cancer: recent advances.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Management of metastatic castration-resistant prostate cancer: recent advances.
@en
type
label
Management of metastatic castration-resistant prostate cancer: recent advances.
@en
prefLabel
Management of metastatic castration-resistant prostate cancer: recent advances.
@en
P2093
P2860
P1433
P1476
Management of metastatic castration-resistant prostate cancer: recent advances.
@en
P2093
Andrew Eichholz
Deborah Mukherji
Johann S De Bono
P2860
P304
P356
10.2165/11633360-000000000-00000
P577
2012-05-01T00:00:00Z
P6179
1020710510